Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Dec;10(6):470-6.
doi: 10.1016/j.jcf.2011.07.007. Epub 2011 Aug 16.

Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

Charles S Haworth  1 , Linda Sharples, Vikki Hughes, Sarah L Elkin, Margaret E Hodson, Steven P Conway, Christine Etherington, J Stuart Elborn, Jackie Rendall, Ella Wheaton, Emma Kadri, Jane Elliott, Helen C Barker, Philip W P Bearcroft, Thinn Hlaing, Juliet E Compston
Affiliations
Free article
Randomized Controlled Trial

Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis

Charles S Haworth et al. J Cyst Fibros. 2011 Dec.
Free article

Abstract

Background: The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.

Methods: Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1g)+vitamin D(3) (800IU).

Results: At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (-0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41.

Conclusions: After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.

PubMed Disclaimer

Publication types